Key result
Antiplatelet therapies protect mice against severe acute lung injury and death from influenza A.
Why the study?
Platelets are activated during influenza virus infection, which is characterized by excessive lung inflammation, but their role in influenza virus pathogenesis and inflammatory responses was unknown.
Does targeted gene deletion or pharmacologic antiplatelet intervention prevent acute lung injury and death in mice infected with influenza A virus?
Does targeted gene deletion or pharmacologic antiplatelet intervention prevent acute lung injury and death in mice infected with influenza A virus?
Antiplatelet therapies protect against severe lung injury and death in murine models of influenza A infection, highlighting a link between hemostasis and viral pathogenesis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for GPIIbIIIa inhibition in viral pneumonia; leaves open translation to human influenza.
Rationale The hallmark of severe influenza virus infection is excessive inflammation of the lungs. Platelets are activated during influenza, but their role in influenza virus pathogenesis and inflammatory responses is unknown. Objectives To determine the role of platelets during influenza A virus infections and propose new therapeutics against influenza. Methods We used targeted gene deletion approaches and pharmacologic interventions to investigate the role of platelets during influenza virus infection in mice. Measurements and Main Results Lungs of infected mice were massively infiltrated by aggregates of activated platelets. Platelet activation promoted influenza A virus pathogenesis. Activating protease-activated receptor 4, a platelet receptor for thrombin that is crucial for platelet activation, exacerbated influenza-induced acute lung injury and death. In contrast, deficiency in the major platelet receptor glycoprotein IIIa protected mice from death caused by influenza viruses, and treating the mice with a specific glycoprotein IIb/IIIa antagonist, eptifibatide, had the same effect. Interestingly, mice treated with other antiplatelet compounds (antagonists of protease-activated receptor 4, MRS 2179, and clopidogrel) were also protected from severe lung injury and lethal infections induced by several influenza strains. Conclusions The intricate relationship between hemostasis and inflammation has major consequences in influenza virus pathogenesis, and antiplatelet drugs might be explored to develop new antiinflammatory treatment against influenza virus infections.
No takes yet. Share an insight, caveat, or question.
Lê et al. (2015) studied Influenza A virus infection. Antiplatelet compounds (eptifibatide, PAR4 antagonists, MRS 2179, clopidogrel) and glycoprotein IIIa gene deletion vs. Untreated or PAR4-activated infected mice was evaluated on Severe acute lung injury and death from influenza virus infection. Antiplatelet therapies (eptifibatide, clopidogrel, MRS 2179, PAR4 antagonists) and glycoprotein IIIa deficiency protected mice from severe lung injury and lethal influenza A infections.
Synapse has enriched 10 related papers. Consider them for comparative context: